Loading…
Fulgent Genetics, Inc.
Fulgent Genetics, Inc. (FLGT) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in El Monte, United States and has 1,315 employees. The company is worth $550.03M. Revenue was $322.67M in fiscal 2025, up 13.8% from the year before. It reported a net loss of $60.51M. The share price is 35.6% below its 52-week high of $31.04. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $8.23M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -78.8% over 5Y.
today you would have $238.90▼ -76.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $26.27 | $18.47 | $28.91 | $29.78 | $100.59 | $52.10 | $12.90 | $3.17 | $4.38 | $11.57 | |
| P/E | 6.1x | — | — | — | 6.4x | 6.1x | 5.8x | — | — | — | — |
| P/S | 3.0x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ETRAElectra Therapeutics, Inc. | $8.75 | — | — | 0.00% | — | $549.21M |
| MYGNMyriad Genetics Inc | $5.76 | — | 1.8x | 0.00% | -32.54% | $550.94M |
| EVHEvolent Health, Inc. | $4.89 | — | 1.4x | 0.00% | -66.97% | $552.86M |
| STTKShattuck Labs, Inc. | $5.42 |
| 2.5x |
| 2.0x |
| 3.0x |
| 1.4x |
| 3.1x |
| 3.6x |
| 8.6x |
| 2.7x |
| 4.2x |
| 11.2x |
| P/B | 1.3x | 0.7x | 0.5x | 0.8x | 0.7x | 2.6x | 2.6x | 3.4x | 1.1x | 1.4x | 3.8x |
| EPS | -$1.97 | -$1.41 | -$5.63 | $4.63 | $16.38 | $8.91 | -$0.02 | -$0.31 | -$0.14 | — |
| Profit margin | -14.23% | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% | 50.82% | -1.26% | -26.26% | -13.40% | -29.26% |
| ROE | -4.20% | -5.44% | -3.77% | -14.77% | 11.32% | 43.79% | 37.64% | -0.50% | -10.96% | -4.63% | -9.81% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 2.6x |
| 0.00% |
| -39.21% |
| $543.97M |
| GMRSGMR Solutions Inc. | $10.00 | — | 1.0x | 0.00% | — | $540.22M |
| SLNSilence Therapeutics plc | $8.68 | — | 10.7x | 0.00% | -90.41% | $539.5M |